Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121681) titled 'Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-RHO in Patients with Autosomal-Dominant Retinitis Pigmentosa (adRP) Due to Rhodopsin (RHO) Gene Mutations' on April 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
RHO-adRP
Intervention:
Low-dose group:Low dose of OPGx-RHO injection
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Low-dose group:5;High-dose group:5;
Countries of Recruitment:
China
To know more, v...